Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7N18

Clostridium botulinum Neurotoxin Serotype A Light Chain Inhibited by a Chiral Hydroxamic Acid

Summary for 7N18
Entry DOI10.2210/pdb7n18/pdb
DescriptorBotulinum neurotoxin type A, ZINC ION, (3R)-3-(4-chlorophenyl)-N,5-dihydroxypentanamide, ... (5 entities in total)
Functional Keywordsbotulinum protease, bont/a, inhibitor, hydrolase, hydrolase-inhibitor complex, hydrolase/inhibitor
Biological sourceClostridium botulinum
Total number of polymer chains2
Total formula weight102549.05
Authors
Silvaggi, N.R.,Allen, K.N. (deposition date: 2021-05-27, release date: 2022-07-06, Last modification date: 2024-01-17)
Primary citationTurner, L.D.,Nielsen, A.L.,Lin, L.,Campedelli, A.J.,Silvaggi, N.R.,Chen, J.S.,Wakefield, A.E.,Allen, K.N.,Janda, K.D.
Use of Crystallography and Molecular Modeling for the Inhibition of the Botulinum Neurotoxin A Protease.
Acs Med.Chem.Lett., 12:1318-1324, 2021
Cited by
PubMed Abstract: Botulinum neurotoxins (BoNTs) are extremely toxic and have been deemed a Tier 1 potential bioterrorism agent. The most potent and persistent of the BoNTs is the "A" serotype, with strategies to counter its etiology focused on designing small-molecule inhibitors of its light chain (LC), a zinc-dependent metalloprotease. The successful structure-based drug design of inhibitors has been confounded as the LC is highly flexible with significant morphological changes occurring upon inhibitor binding. To achieve greater success, previous and new cocrystal structures were evaluated from the standpoint of inhibitor enantioselectivity and their effect on active-site morphology. Based upon these structural insights, we designed inhibitors that were predicted to take advantage of π-π stacking interactions present in a cryptic hydrophobic subpocket. Structure-activity relationships were defined, and X-ray crystal structures and docking models were examined to rationalize the observed potency differences between inhibitors.
PubMed: 34413962
DOI: 10.1021/acsmedchemlett.1c00325
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.03 Å)
Structure validation

246704

PDB entries from 2025-12-24

PDB statisticsPDBj update infoContact PDBjnumon